| Ytd | -39.16% | |
| 1y | -87.09% |
| Open | 52.81 | Prev Close | 52.55 | Low | 51.51 | High | 53.17 | Mkt Cap | 145.87M |
| Vol | 2.88K | Avg Vol | 77.31K | EPS | -35.82 | P/E | N/A | Forward P/E | -0.41 |
| Beta | 2.37 | Short Ratio | 0.10 | Inst. Own | 46.69% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 53.01 | 200-d Avg | 73.45 | 1yr Est | 1.83 |
SPRB News
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developin
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developin
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Spruce Biosciences (NASDAQ:SPRB) wi
Jones Trading analyst Catherine Novack initiates coverage on Spruce Biosciences (NASDAQ:SPRB) wit
Data Highlight TA-ERT's Potential as the First Disease-Modifying Treatment Option for MPS IIIB,
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Spruce Biosciences (NASDAQ:SPRB) wit
Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outpe
SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. (OTC:SPRB) reported quarterly losses of $(8.94) p
Craig-Hallum analyst Albert Lowe initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Bu
(Editor’s note: The futures and ETFs data were updated.) U.S. stock futures rose on Tuesday follo
Spruce Biosciences (SPRB) shares drop 21% in premarket trading following a $60 million public stock
Amazon Inc (NASDAQ: AMZN) rose in pre-market trading after announcing a strategic collaboration with
Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outpe
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Spruce Biosciences (NASDAQ:SPRB) wi
SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. (OTC:SPRB) reported quarterly losses of $(36.25)
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Spruce Biosciences (NASDAQ:SPRB) wit
Spruce Biosciences announced the successful completion of Type B meetings with the U.S. Food and Dru
Harbour BioMed exercises its warrant to buy Spruce Biosciences shares, raising its stake to about 3.
Spruce Biosciences, Inc. (Spruce) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on
Oppenheimer analyst Leland Gershell initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a
HC Wainwright & Co. analyst Raghuram Selvaraju assumes Spruce Biosciences (NASDAQ:SPRB) with
Leerink Partners analyst Joseph Schwartz upgrades Spruce Biosciences (NASDAQ:SPRB) from Market Pe
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the com
The Dow Jones closed lower by around 700 points on Tuesday. When insiders purchase or sell shares, i